1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > GlaxoSmithKline Plc - Product Pipeline Review - 2016

GlaxoSmithKline Plc - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 406 pages

GlaxoSmithKline Plc - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘GlaxoSmithKline Plc - Product Pipeline Review - 2016’, provides an overview of the GlaxoSmithKline Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GlaxoSmithKline Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of GlaxoSmithKline Plc
- The report provides overview of GlaxoSmithKline Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses GlaxoSmithKline Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features GlaxoSmithKline Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate GlaxoSmithKline Plc’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for GlaxoSmithKline Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding GlaxoSmithKline Plc’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

GlaxoSmithKline Plc - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 8
GlaxoSmithKline Plc Snapshot 9
GlaxoSmithKline Plc Overview 9
Key Information 9
Key Facts 9
GlaxoSmithKline Plc - Research and Development Overview 10
Key Therapeutic Areas 10
GlaxoSmithKline Plc - Pipeline Review 22
Pipeline Products by Stage of Development 22
Pipeline Products - Monotherapy 23
Pipeline Products - Combination Treatment Modalities 24
Pipeline Products - Partnered Products 25
Pipeline Products - Out-Licensed Products 28
GlaxoSmithKline Plc - Pipeline Products Glance 30
GlaxoSmithKline Plc - Late Stage Pipeline Products 30
GlaxoSmithKline Plc - Clinical Stage Pipeline Products 33
GlaxoSmithKline Plc - Early Stage Pipeline Products 39
GlaxoSmithKline Plc - Unknown Stage Pipeline Products 43
GlaxoSmithKline Plc - Drug Profiles 44
gepirone hydrochloride ER 44
GSK-257049 46
GSK-2696273 50
mepolizumab 51
melanoma lysate vaccine 54
(fluticasone furoate + umeclidinium bromide + vilanterol trifenatate) 56
(fluticasone furoate + vilanterol trifenatate) 58
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine 60
albiglutide 61
ambrisentan 64
AS15 + recMAGE-A3 66
belimumab 68
bupropion hydrochloride ER 72
Ebola [Zaire] vaccine 73
fluticasone furoate 76
GSK-1437173A 79
inotersen sodium 81
KD-295 82
losmapimod 83
meningococcal [serotype B] vaccine 85
retosiban 87
tafenoquine succinate 88
vilanterol trifenatate 90
zanamivir 92
(batefenterol succinate + fluticasone furoate) 94
(fluticasone furoate + levocabastine hydrochloride) 95
alitretinoin 96
batefenterol 98
CAD-106 100
camicinal 102
dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide 104
danirixin 105
daprodustat 107
fluticasone furoate + umeclidinium bromide 109
gepotidacin mesylate 110
group B Streptococcus (trivalent) vaccine 112
GSK-2189242A 114
GSK-2231392A 115
GSK-2245035 116
GSK-2256098 118
GSK-2269557 120
GSK-2302032A 121
GSK-2315698 + GSK-2398852 122
GSK-2330672 123
GSK-2339345 124
GSK-239512 125
GSK-2586881 126
GSK-2696274 127
GSK-2696275 128
GSK-2789869A 129
GSK-2830930A 130
GSK-2838504A 131
GSK-2862277 132
GSK-3003891A 133
GSK-3196165 134
GSK-3277511A 136
GSK-692342 137
GSK-933776 139
GVXNSD-133 140
hepatitis C vaccine 1 141
malaria vaccine 142
mapatumumab 144
maribavir 146
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine 148
otelixizumab 149
respiratory syncytial virus vaccine 151
rilapladib 152
Streptococcal pneumonia vaccine 3 153
umeclidinium bromide 154
GSK-2302025A 156
GSK-2636771 157
GSK-525762 158
HIV [strains C1086 + TV1] (bivalent) vaccine 159
pazopanib hydrochloride + pembrolizumab 160
TDEN-PIV 161
(amlodipine besylate + rosuvastatin calcium) 162
(candesartan cilexetil + hydrochlorothiazide) 163
(diphtheria + pertussis (acellular) + tetanus) vaccine 164
1790GAHB 165
EcoXyn-4V 166
epelsiban besylate 167
FP-1039 169
GSK-1940029 171
GSK-2130579A 172
GSK-2241658A 173
GSK-2256294 174
GSK-2330811 175
GSK-2618960 176
GSK-2646264 177
GSK-2654909A 178
GSK-2654911A 179
GSK-2789868A 180
GSK-2798745 181
GSK-2800528 182
GSK-2816126 183
GSK-2831781 184
GSK-2849330 185
GSK-2857916 186
GSK-2878175 187
GSK-2879552 188
GSK-2881078 189
GSK-2981278 190
GSK-2981710 191
GSK-2982772 192
GSK-3008348 193
GSK-3117391 194
GSK-3174998 195
GSK-3206640A 196
GSK-3206641A 197
GSK-3389245A 198
hepatitis C vaccine 2 199
HIV vaccine 1 200
HIV vaccine 5 201
IMP-731 202
influenza [strain A/H5N1] vaccine 203
influenza vaccine 2 205
montelukast sodium 206
omipalisib 207
oxytocin 209
RSV-001 210
Staphylococcus aureus vaccine 211
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 212
BLyS-gel 213
Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis 214
Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa 215
GSK-030 216
GSK-1795091 217
GSK-2041706 218
GSK-214096 219
GSK-2225745 220
GSK-2394002 221
GSK-2656157 222
GSK-2795039 223
GSK-2820151 224
GSK-3039294 225
GSK-3277509A 226
GSK-3277510A 227
GSK-3326595 228
GSK-3359609 229
GSK-6288B 230
GSK-8853 231
GSKJ-4 232
GW-610742 233
HIV vaccine 2 234
influenza vaccine 235
marburg vaccine 236
meningococcal vaccine 2 237
Monoclonal Antibody Conjugate for Oncology 238
raxibacumab 239
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis 240
Small Molecule 1 for Malaria 241
Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer 242
Small Molecule 2 for Malaria 244
Small Molecule 2 for Tuberculosis 245
Small Molecule 2 to Inhibit Histone Methyltransferases for Cancer 246
Small Molecule 3 to Inhibit Histone Methyltransferases for Cancer 247
Small Molecule for Hypertension and Insulin Resistance 248
Small Molecule to Activate AMPK for Type 2 Diabetes 249
Small Molecule to Agonize S1P1 for Multiple Sclerosis 250
Small Molecules to Inhibit InhA for Tuberculosis 251
Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis 252
staphylococci aureus vaccine 253
Streptococcal pneumonia vaccine 254
TC-2153 255
tuberculosis vaccine 256
Vaccine for Alzheimer's Disease 257
Vaccine for Cancer 258
bacterial vaccine 259
bacterial vaccine 2 260
Drug for Chronic Liver Disease 261
Drugs to Antagonize T-Cell Receptor for Oncology 262
Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis 263
GSK-137647A 264
GSK-343 265
GSK-5959 266
GSKJ-1 267
Proteins for Musculoskeletal Disorders 268
Pseudomonas aeruginosa vaccine 269
Small Molecule for Tuberculosis 270
Small Molecule to Antagonize FFA4 for Undisclosed Indication 271
Small Molecule to Inhibit Histone Deacetylases for Oncology 272
Small Molecules for HIV-1 Infection 273
Small Molecules for Tuberculosis 274
Small Molecules for Undisclosed Indication 275
Small Molecules to Antagonize Folate Receptor for Tuberculosis 276
Small Molecules to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology 277
Small Molecules to Inhibit Falcipain for Malaria 278
Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis 279
Small Molecules to Inhibit RNA Polymerase for Hepatitis C 280
(paratyphoid + typhoid) vaccine 281
GlaxoSmithKline Plc - Pipeline Analysis 282
GlaxoSmithKline Plc - Pipeline Products by Target 282
GlaxoSmithKline Plc - Pipeline Products by Route of Administration 295
GlaxoSmithKline Plc - Pipeline Products by Molecule Type 296
GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action 298
GlaxoSmithKline Plc - Recent Pipeline Updates 306
GlaxoSmithKline Plc - Dormant Projects 354
GlaxoSmithKline Plc - Discontinued Pipeline Products 363
Discontinued Pipeline Product Profiles 364
GlaxoSmithKline Plc - Company Statement 376
GlaxoSmithKline Plc - Locations And Subsidiaries 379
Head Office 379
Other Locations and Subsidiaries 379
GlaxoSmithKline Plc - Key Manufacturing Facilities 390
Appendix 391
Methodology 391
Coverage 391
Secondary Research 391
Primary Research 391
Expert Panel Validation 391
Contact Us 391
Disclaimer 392

List of Tables
GlaxoSmithKline Plc, Key Information 23
GlaxoSmithKline Plc, Key Facts 23
GlaxoSmithKline Plc - Pipeline by Indication, 2016 25
GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016 36
GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016 37
GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016 38
GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016 39
GlaxoSmithKline Plc - Partnered Products/ Combination Treatment Modalities, 2016 40
GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016 42
GlaxoSmithKline Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 43
GlaxoSmithKline Plc - Pre-Registration, 2016 44
GlaxoSmithKline Plc - Filing rejected/Withdrawn, 2016 45
GlaxoSmithKline Plc - Phase III, 2016 46
GlaxoSmithKline Plc - Phase II, 2016 47
GlaxoSmithKline Plc - Phase I, 2016 50
GlaxoSmithKline Plc - IND/CTA Filed, 2016 53
GlaxoSmithKline Plc - Preclinical, 2016 54
GlaxoSmithKline Plc - Discovery, 2016 56
GlaxoSmithKline Plc - Unknown, 2016 57
GlaxoSmithKline Plc - Pipeline by Target, 2016 296
GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016 309
GlaxoSmithKline Plc - Pipeline by Molecule Type, 2016 310
GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action, 2016 312
GlaxoSmithKline Plc - Recent Pipeline Updates, 2016 320
GlaxoSmithKline Plc - Dormant Developmental Projects,2016 368
GlaxoSmithKline Plc - Discontinued Pipeline Products, 2016 377
GlaxoSmithKline Plc, Other Locations 393
GlaxoSmithKline Plc, Subsidiaries 393
GlaxoSmithKline Plc, Key Manufacturing Facilities 404

List of Figures
GlaxoSmithKline Plc - Pipeline by Top 10 Indication, 2016 25
GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016 36
GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016 37
GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016 38
GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016 39
GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016 42
GlaxoSmithKline Plc - Pipeline by Top 10 Target, 2016 296
GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016 309
GlaxoSmithKline Plc - Pipeline by Top 10 Molecule Type, 2016 310
GlaxoSmithKline Plc - Pipeline Products by Top 10 Mechanism of Action, 2016 312

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.